PRESTO 3 – An international, simulated-use study to assess nurses’ preferences between two lanreotide injection syringes (Somatuline Autogel vs Pharmathen) for patients with neuroendocrine tumors (NETs) and/or acromegaly

#3787

Introduction: Somatostatin analogues (SSAs) are often used to treat patients with NETs and acromegaly. The Pharmathen syringe is now available in Europe and the USA for depot injection. It is important for decision making when using SSAs that there is confidence in and ease of use with any syringe.

Aim(s): PRESTO 3 compared nurses’ preference for the Somatuline Autogel syringe vs the Pharmathen syringe after testing into injection pads.

Materials and methods: This international, simulated-use study included oncology and/or endocrinology nurses (initial planned sample size, 92) experienced in treating patients with NETs and/or acromegaly for ≥1 year and responsible for administering long-acting SSAs with ≥2 syringe types. Each nurse tested both syringes twice in a randomised order, before completing an electronic preference survey. The primary endpoint was overall preference (%, 95% confidence interval) for Somatuline Autogel vs the Pharmathen syringe, assessed using a one-sample exact binomial test.

Conference:

Presenting Author: Ferone D

Authors: Grossman A, Martin W, Williams J, Houchard A, Pommie C,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Simulated use study, Somatostatin analogues, User preference,